A recent study indicates that patients who come off new GLP-1 drugs like Wegovy and Mounjaro tend to recover shed pounds at a significantly accelerated pace than those who halt traditional lifestyle regimens.
Research printed in a major medical journal demonstrates that while overweight individuals can lose substantial amounts of their total mass while undergoing treatment, the weight is regained at an average rate of nearly a kilo each month once they quit.
"Users using such treatments need to be cognizant of the danger of quick rebound weight gain when the therapy concludes," cautioned researcher Dr. Susan Jebb.
This pace of regain means a return to starting weight in about one and a half years.
Weighing Approaches
The analysis, which examined dozens of trials involving thousands of patients, contrasted the outcomes of GLP-1 agonists with conventional dieting.
Scientists emphasize that people who lose weight through lifestyle changes alone usually see a less rapid weight regain—approximately 100 grams monthly—after stopping.
Explaining the Quick Regain
Experts believe the mechanism of the drugs explains the heightened weight return.
These medications mimic a natural hormone called GLP-1, which controls feelings of fullness.
"Long-term administration of GLP-1 levels several times higher than the body's typical production might result in the body to generate a reduced amount of its own natural hormone, and may also diminish responsiveness to its effects," explained Dr. Adam Collins, a nutrition expert.
"Withdrawal of this GLP-1 'fix' means hunger is uncontrolled, making excessive eating far more likely."
An Ongoing Issue?
Health authorities recommend the jabs for individuals with weight-linked health risks, accompanied by prescribed lifestyle changes.
Professionals argue that, due to the likelihood of relapse, the treatment might need to be ongoing.
This opinion is supported by pharmaceutical companies, who say that the findings "emphasize the chronic nature of excess weight," akin to managing diseases like high blood pressure.
User Accounts
Individuals who have discontinued the medication explain a sudden return of hunger.
"It felt as if a switch that goes on and you're instantly starving," said an individual.
This difficulty is exacerbated if patients have not established sustainable dietary or behavioural changes during therapy.
Widespread Use
Survey data show that a significant number of people in the UK have used these injections in the past year, with interest remaining high.
- Use is higher among females than males.
- The 40s and 50s age group shows the greatest level of interest.
- Many obtain the medications through private prescriptions rather than public health services.
Finally, researchers caution that while GLP-1 drugs are powerful agents for weight loss, they are not a standalone solution and lasting health benefits hinges on ongoing lifestyle changes.
